Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenQuadfi Immunogenicity and Safety in Infants and Toddlers
NCT03691610Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of meningococcal A conjugate vaccine in meningococcal infection (4 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at 30 Days Post Second Dose. Started Oct 2018; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT03691610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691610.